For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Altimmune’s lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...

Real-time index price for TSX Composite Weight Index (TXCE), along with buy or sell indicators, analysis, charts, historical ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Leigh-Anne Lagden was given a free weight loss injection in exchange for social media promotion but claims they told her to ...

BIGBANG’s G-Dragon is back—and topping music charts across the globe! On October 31 at 6 p.m. KST, G-Dragon made his long-awaited solo return with his new pre-release single “POWER.” ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage ... its shortage list to note that the 0.25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy ...